The emergency state caused by COVID-19 saw the use of immunomodulators despite the
absence of robust research. To date, the results of relatively few randomized controlled trials …

The global panic of the novel coronavirus disease 2019 (COVID-19) triggered by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent requirement …

The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …

With the onset of the global pandemic in 2020 of Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain …

ABSTRACT Introduction SARS-CoV-2, the virus that causes COVID-19, elicits a variety of
host responses ranging from asymptomatic or mild illness in most people, to severe disease …

Background Immunomodulatory therapy has been extensively studied in randomized
clinical trials for the treatment of patients hospitalized for COVID-19 with inconsistent …

Objective To update the EULAR 2020 systematic literature review (SLR) on efficacy and
safety of immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a EULAR …

COVID-19 is an acute respiratory syndrome caused by SARS-COV-2 which has now
become a huge pandemic worldwide. The immunopathogenesis of COVID-19 has been …

Background Although immunomodulators have established benefit against the new
coronavirus disease (COVID-19) in general, it is uncertain whether such agents improve …

Abstract Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2),
coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This …